However, only PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) entered routine clinical practice in patients with non-small-cell lung cancer (NSCLC) [5,6,7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.